MF59®-adjuvanted seasonal influenza vaccine

Aging Health

Volumn 5, Issue 4, 2009, Pages 475-481

  Puig Barberà, Joan ^a  

^a Centre Salut Pública   (Spain)

Author keywords

Adjuvant; Antigenic variation; Emulsion; Influenza; Influenza vaccine; Influenza, human; Prevention control; Squalene; Subunit; Vaccines; Vulnerable populations

Indexed keywords

IDFLU; INFLUENZA VACCINE; INTANZA; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYSORBATE 80; SORBITAN TRIOLEATE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; ERYTHEMA; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE INDURATION; MALAISE; MYALGIA; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PAIN; PNEUMONIA; SEASONAL VARIATION; SENESCENCE; SYSTEMIC DISEASE; VIRUS STRAIN;

EID: 70249120371     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.09.35     Document Type: Article

References (52)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al.: The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27), 5086-5096 (2007).
2. Whitley RJ, Monto AS: Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J. Infect. Dis. 194(Suppl. 2), S133-S138 (2006).
3. Barker WH, Borisute H, Cox C: A study of the impact of influenza on the functional status of frail older people. Arch. Intern. Med. 158(6), 645-650 (1998).
4. McElhaney JE: The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23(Suppl. 1), S10-S25 (2005).
5. Fiore AE, Shay DK, Broder K et al.: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep. 57(RR-7), 1-60 (2008).
6. Vu T, Farish S, Jenkins M, Kelly H: A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20(13), 1831-1836 (2002).
7. Puig-Barbera J, Marquez CS: Effectiveness of influenza vaccine in the elderly. A critical review of the bibliography. Med. Clin. (Barc.) 105(17), 645-648 (1995).
8. Jefferson T: Influenza vaccination: policy versus evidence. BMJ 333(7574), 912-915 (2006).
9. Glezen WP, Simonsen L: Commentary: Benefits of influenza vaccine in US elderly - new studies raise questions. Int. J. Epidemiol. 35(2), 352-353 (2006).
10. Hannoun C, Megas F, Piercy J: Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103(1-2), 133-138 (2004).
11. Carrat F, Flahault A: Influenza vaccine: the challenge of antigenic drift. Vaccine 25(39-40), 6852-6862 (2007).
12. Lin YP, Gregory V, Bennett M, Hay A: Recent changes among human influenza viruses. Virus Res. 103(1-2), 47-52 (2004).
13. Shaw MW, Xu X, Li Y et al.: Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303(1), 1-8 (2002).
14. Legrand J, Vergu E, Flahault A: Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24(44-46), 6605-6611 (2006).
15. Simonsen L, Clarke MJ, Williamson GD et al.: The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Public Health 87(12), 1944-1950 (1997).
16. Treanor J: Influenza vaccine - outmaneuvering antigenic shift and drift. N. Engl. J. Med. 350(3), 218-220 (2004).
17. Kumar R, Burns EA: Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev. Vaccines 7(4), 467-479 (2008).
18. O'Hagan DT: MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6(5), 699-710 (2007).
19. Moser C, Metcalfe IC, Viret JF: Virosomal adjuvanted antigen delivery systems. Expert. Rev. Vaccines 2(2), 189-196 (2003).
20. Belshe RB, Newman FK, Wilkins K et al.: Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25(37-38), 6755-6763 (2007).
21. Holland D, Booy R, De Looze F et al.: Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).
22. Gluck R, Mischler R, Durrer P et al.: Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129-1132 (2000).
23. Gerhard W, Mozdzanowska K, Zharikova D: Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12(4), 569-574 (2006).
24. Fiers W, De Filette M, Birkett A, Neirynck S, Min JW: A 'universal' human influenza A vaccine. Virus Res. 103(1-2), 173-176 (2004).
25. Nicolas JF, Guy B: Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201-1214 (2008).
26. Mutsch-M, Zhou W, Rhodes P et al.: Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
27. Laurent PE, Bonnet S, Alchas P et al.: Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007).
28. Belshe RB, Newman FK, Cannon J et al.: Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351(22), 2286-2294 (2004).
29. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M et al.: Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 270(3), 454-459 (2009).
30. Schijns VE: Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21(1-3), 75-85 (2001).
31. de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM: Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23(Suppl. 1), S39-S49 (2005).
32. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R: Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
33. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R: Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472-3475 (2001).
34. Ruf BR, Colberg K, Frick M, Preusche A: Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32(4), 191-198 (2004).
35. Pregliasco F, Mensi C, Serpilli W et al.: Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 13(1), 38-43 (2001).
36. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B: Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26(1), 119-127 (2007).
37. Puig-Barbera J, Gonzalez-Vidal D: MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev. Vaccines 6(5), 659-665 (2007).
38. Del Giudice G, Hilbert AK, Bugarini R et al.: An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24(16), 3063-3065 (2006).
39. Ansaldi F, Bacilieri S, Durando P et al.: Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26(12), 1525-1529 (2008).
40. Puig-Barbera J, Diez-Domingo J, Perez HS, Belenguer VA, Gonzalez VD: Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23(3), 283-289 (2004).
41. Puig-Barbera, Diez-Domingo J et al.: Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25(42), 7313-7321 (2007).
42. Radosevic K, Rodriguez A, Mintardjo R et al.: Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 26(29-30), 3640-3646 (2008).
43. Del Giudice G, Fragapane E, Bugarini R et al.: Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol. 13(9), 1010-1013 (2006).
44. Leroux-Roels I, Borkowski A, Vanwolleghem T et al.: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007).
45. Levie K, Leroux-Roels I, Hoppenbrouwers K et al.: An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198(5), 642-649 (2008).
46. Mosca F, Tritto E, Muzzi A et al.: Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
47. De Donato S, Granoff D, Minutello M et al.: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17(23-24), 3094-3101 (1999).
48. Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17-19), 2673-2680 (2001).
49. Squarcione S, Sgricia S, Biasio LR, Perinetti E: Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21(11-12), 1268-1274 (2003).
50. Banzhoff A, Nacci P, Podda A: A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49(3), 177-184 (2003).
51. Baldo V, Baldovin T, Floreani A, Minuzzo M, Trivello R: Response to influenza vaccine in people with non-protective HI antibody titers. Eur. J. Epidemiol. 21(11), 843-845 (2006).
52. Lawrence G, Boyd I, McIntyre P, Isaacs D: Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun. Dis. Intell. 28(3), 324-338 (2004).